Thumbnail Image
Publication

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

; 
Snee, M
; 
Ashcroft, Linda
; 
Appel, W
; 
Barlesi, F
; 
Bhatnagar, A
; 
Bezjak, A
; 
Cardenal, F
; 
Fournel, P
; 
Harden, S
... show 10 more
Citations
Altmetric:
Abstract
Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer.
Authors
Faivre-Finn, Corinne
Snee, M
Ashcroft, Linda
Appel, W
Barlesi, F
Bhatnagar, A
Bezjak, A
Cardenal, F
Fournel, P
Harden, S
Le Pechoux, C
McMenemin, R
Mohammed, N
O'Brien, M
Pantarotto, J
Surmont, V
Van Meerbeeck, J
Woll, P
Lorigan, Paul C
Blackhall, Fiona H
Affiliation
Division of Molecular and Clinical Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester
Description
Date
2017-06-19
Publisher
Collections
All Christie Publications
Show all metadata
Files
Thumbnail Image
Open access full text article
Adobe PDF, 486.28 KB
Keywords
Type
Article
Citation
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. 2017 Lancet Oncol
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/620446
Embedded videos